Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy

See allHide authors and affiliations

Science Translational Medicine  04 Oct 2017:
Vol. 9, Issue 410, eaan5616
DOI: 10.1126/scitranslmed.aan5616


Renin-angiotensin system (RAS) inhibitors (RASi)—widely prescribed for the treatment of cardiovascular diseases—have considerable potential in oncology. The RAS plays a crucial role in cancer biology and affects tumor growth and dissemination directly and indirectly by remodeling the tumor microenvironment. We review clinical data on the benefit of RASi in primary and metastatic tumors and propose that, by activating immunostimulatory pathways, these inhibitors can enhance immunotherapy of cancer.

This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

View Full Text

Stay Connected to Science Translational Medicine